Glenmark’s US arm gets USFDA’s approval for Olopatadine Hydrochloride Ophthalmic Solution

21 Mar 2025 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, USA has received final approval by the United States Food & Drug Administration (USFDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), determined by the FDA to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA.

According to Nielsen syndicated data for the latest 52 weeks’ period ending February 22, 2025, the Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC) market3 achieved annual sales of around $50.7 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 


Glenmark Pharma Share Price

1375.40 -2.15 (-0.16%)
15-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1705.15
Dr. Reddys Lab 1155.80
Cipla 1481.40
Lupin 2012.05
Zydus Lifesciences 884.20
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...